Leap Investments’s Aquestive Therapeutics AQST Stock Holding History

Leap Investments’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-71,809	Closed	-$418K	–	360
2019 Q4	$418K	Buy	+71,809	New	+$374K	0.2%	182

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Leap Investments's AQST Position: Q1 2020 in Review

Leap Investments sold out of Aquestive Therapeutics (AQST) in Q1 2020, closing a stake of 71,809 shares — an estimated $418K sold.

Leap Investments first reported a position in AQST in Q4 2019 and held it in 1 quarter. The position peaked at $418K in Q4 2019. 42 funds tracked by Wall St. Rank hold AQST as of Q1 2020.

Leap Investments reported no remaining Aquestive Therapeutics position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 71,809 Aquestive Therapeutics shares in Q1 2020, an estimated $418K.
Leap Investments first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 1 quarter.
Leap Investments's Aquestive Therapeutics position peaked at $418K in Q4 2019.
42 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.